title: [The expression and clinical significance of miR-203 in pediatric acute leukemia].
abstract: OBJECTIVE
  To investigate the methylation, expression and clinical significance of miR-203 in pediatric acute leukemia.
  
  
  METHODS
  The methylation status of miR-203 promoter CpG islands was detected with methylation-specific polymerase chain reaction. The expression of miR-203 was detected by Taqman real- time quantitative polymerase chain reaction. And the clinical significance of miR-203 in pediatric acute leukemia (ALL) was also analyzed.
  
  
  RESULTS
  The promoter of miR-203 was unmethylated in all of 31 pediatric acute lymphoblastic leukemia, all of 15 pediatric acute myeloid leukemia (AML) and all of 23 controls. The relative expression levels of miR-203 in controls, pediatric acute leukemia, ALL and AML were 16.93±6.31, 48.97±10.38, 55.88±12.91, 24.28±9.10 respectively. The results indicated that miR-203 was significantly up- regulated in pediatric acute leukemia (P=0.011) and ALL (P=0.009), not in pediatric AML (P=0.514) compared with control. The expression of miR-203 was significantly related with the gender, immunophenotype, chromosome, fusion gene, BCR-ABL, SIL-TAL1 and prednisone experiment in pediatric ALL and the gender, chromosome, fusion gene, SIL-TAL1 in pediatric acute leukemia (P<0.05). And in risk stratification pairwise comparisons, the expression of miR-203 in the medium-risk and high-risk groups appeared significantly different (P=0.022).
  
  
  CONCLUSIONS
  miR-203 may not be regulated with methylation mechanism in pediatric acute leukemia. miR- 203 may be a protooncogene involved in the formation of pediatric acute leukemia and ALL. Further analyses indicated that high expression of miR-203 may be associated with poor prognosis of pediatric ALL and acute leukemia.
authors.affiliation: Department of Hematology-Oncology, Children's Hospital of Soochow University, Suzhou 215003, China.
authors.forename: Na
authors.initials: N
authors.lastname: Wang
authors.forename: Jian
authors.initials: J
authors.lastname: Pan
authors.forename: Lan
authors.initials: L
authors.lastname: Cao
authors.forename: Jun
authors.initials: J
authors.lastname: Lu
authors.forename: Pei-fang
authors.initials: PF
authors.lastname: Xiao
authors.forename: Wen-li
authors.initials: WL
authors.lastname: Zhao
authors.forename: Shao-yan
authors.initials: SY
authors.lastname: Hu
authors.forename: Yi-huan
authors.initials: YH
authors.lastname: Chai
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D018899:CpG Islands; D019175:DNA Methylation; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007223:Infant; D007938:Leukemia; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000378:metabolism; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000378:metabolism; D011401:Promoter Regions, Genetic
chemical_list: C546703:MIRN203 microRNA, human; D035683:MicroRNAs